Cell therapy for CD7-positive blood cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be CD7-positive (at least 30% of cells show CD7 by special testing).
- You must have a blood cancer that has come back or not responded to treatment.
- You must be between 3 and 70 years old.
- Your liver, kidneys, and other organs must be working well enough for the study.
- You must not have any active serious infections, heart problems, or other major illnesses.
- You must agree to use effective birth control if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
This study tests a new type of immune cell therapy for people whose cancer cells have a specific marker called CD7. The treatment uses modified immune cells (CAR T-cells) to find and attack the cancer. It might help if other treatments haven't worked or the cancer has returned.
This trial tests a new treatment called PA3-17, which uses your own immune cells modified to target and kill cancer cells that have a protein called CD7 on them. It is designed for patients with T-cell leukemia or lymphoma that has come back or did not respond to prior treatments.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.